Sugi Predict

Sugi Predict / Compounds / Testosterone

Testosterone

Testosterone

SCHEMBL11226131

CCCC(=O)O.C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AR

The experimentally established mechanism targets of Testosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR known ✓ P10275 4/20 0.80
▸ LMNA P02545 8/20 0.80
▸ CYP3A4 P08684 8/20 0.80
▸ TSHR P16473 5/20 0.80
▸ CYP19A1 P11511 5/20 0.80
▸ MAPT P10636 5/20 0.80
▸ HSD17B10 Q99714 4/20 0.80
▸ SHBG P04278 4/20 0.80
▸ SERPINA6 P08185 4/20 0.80
▸ NR3C1 P04150 4/20 0.80
▸ PGR P06401 4/20 0.80
▸ MAPK1 P28482 4/20 0.80
▸ GPBAR1 Q8TDU6 3/20 0.80
▸ SIGMAR1 Q99720 3/20 0.80
▸ SNCA P37840 2/20 0.80
▸ CACNA1C Q13936 2/20 0.80
▸ CYP51A1 Q16850 2/20 0.80
▸ OR51E2 Q9H255 1/20 0.80
▸ ALDH1A1 P00352 4/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Testosterone SCHEMBL14694321 0.95 LMNA (0.78) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL14694449 0.94 LMNA (0.77) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL8075829 0.94 LMNA (0.83) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL42688 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL5078098 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL5082498 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT
Behenic Acid SCHEMBL11429128 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL2023832 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL5078860 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT
Testosterone SCHEMBL5080100 0.93 LMNA (0.75) LMNACYP3A4TSHRCYP19A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014144366-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC. (US) 2014-09-18 — — WO claimed
US-20140255473-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC (US) 2014-09-11 — — US claimed
EP-2744482-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MonoSol Rx, LLC (US) 2014-06-25 — — EP claimed
US-20140017299-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC (US) 2014-01-16 — — US claimed
WO-2013026002-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC (US) 2013-02-21 — — WO claimed
US-20130045271-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC (US) 2013-02-21 — — US claimed
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 — — US disclosed
US-20250281509-A1 SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER THE JOHNS HOPKINS UNIVERSTY 2025-09-11 — — US disclosed
WO-2023223235-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF PURNA PHARMACEUTICALS NV (BE) 2023-11-23 — — WO disclosed
CN-116528876-A Biodegradable polymer delivery system for prolonged delivery of testosterone 托尔玛国际有限公司 2023-08-01 — — CN disclosed
CN-116077454-A Orodispersible dosage unit containing estetrol component 埃斯特拉有限责任公司 2023-05-09 — — CN disclosed
CN-116077455-A Orodispersible dosage unit containing estetrol component 埃斯特拉有限责任公司 2023-05-09 — — CN disclosed
CN-107750157-B Orodispersible tablets containing estetrol 埃斯特拉私人有限责任公司 2021-07-13 — — CN disclosed
WO-2013026002-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC (US) 2013-02-21 — — WO disclosed
US-20130045271-A1 STEROID HORMONE DELIVERY SYSTEMS AND METHODS OF PREPARING THE SAME MONOSOL RX, LLC (US) 2013-02-21 — — US disclosed
US-4329296-A Branched chain and cycloaliphatic esters of the androstane and oestrane series and pharmaceutical compositions containing same AKZONA INCORPORATED (US) 1982-05-11 — — US disclosed
US-4312864-A ANDROGENIC, ANABOLIC, ESTROGENIC, ANTIESTROGENIC AKZONA INCORPORATED (US) 1982-01-26 — — US disclosed
US-4307086-A ANTIESTROGENS AKZONA INCORPORATED (US) 1981-12-22 — — US disclosed
US-4307087-A ANTIESTROGENS AKZONA INCORPORATED (US) 1981-12-22 — — US disclosed
US-4212864-A ANDROGENIC, ANABOLIC, ESTROGENIC AND ANTI-ESTROGENIC PROPERTIES AKZONA INCORPORATED (US) 1980-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR AR 14/4885LMNA 796/4885CYP3A4 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.